Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of BRL 789.22 billion. The enterprise value is 853.27 billion.

Market Cap	789.22B
Enterprise Value	853.27B

Important Dates

The next confirmed earnings date is Thursday, May 7, 2026.

Earnings Date	May 7, 2026
Ex-Dividend Date	Mar 12, 2026

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	88.87%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 16.84 and the forward PE ratio is 14.92.

PE Ratio	16.84
Forward PE	14.92
PS Ratio	4.87
PB Ratio	6.34
P/TBV Ratio	n/a
P/FCF Ratio	15.15
P/OCF Ratio	14.30
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.63, with an EV/FCF ratio of 16.38.

EV / Earnings	18.20
EV / Sales	5.82
EV / EBITDA	11.63
EV / EBIT	14.51
EV / FCF	16.38

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.13.

Current Ratio	1.55
Quick Ratio	1.23
Debt / Equity	1.13
Debt / EBITDA	1.73
Debt / FCF	2.70
Interest Coverage	11.54

Financial Efficiency

Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 26.86%.

Return on Equity (ROE)	40.66%
Return on Assets (ROA)	12.52%
Return on Invested Capital (ROIC)	26.86%
Return on Capital Employed (ROCE)	25.03%
Weighted Average Cost of Capital (WACC)	6.02%
Revenue Per Employee	9.54M
Profits Per Employee	2.76M
Employee Count	17,000
Asset Turnover	0.50
Inventory Turnover	3.58

Taxes

In the past 12 months, Gilead Sciences has paid 7.08 billion in taxes.

Income Tax	7.08B
Effective Tax Rate	13.13%

Stock Price Statistics

The stock price has increased by +9.37% in the last 52 weeks. The beta is 0.40, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.40
52-Week Price Change	+9.37%
50-Day Moving Average	349.78
200-Day Moving Average	316.45
Relative Strength Index (RSI)	29.51
Average Volume (20 Days)	117

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.45

Income Statement

In the last 12 months, Gilead Sciences had revenue of BRL 162.17 billion and earned 46.87 billion in profits. Earnings per share was 37.34.

Revenue	162.17B
Gross Profit	127.86B
Operating Income	65.09B
Pretax Income	53.96B
Net Income	46.87B
EBITDA	80.29B
EBIT	65.09B
Earnings Per Share (EPS)	37.34

Balance Sheet

The company has 52.95 billion in cash and 140.68 billion in debt, giving a net cash position of -71.35 billion.

Cash & Cash Equivalents	52.95B
Total Debt	140.68B
Net Cash	-71.35B
Net Cash Per Share	n/a
Equity (Book Value)	124.58B
Book Value Per Share	100.76
Working Capital	35.96B

Cash Flow

In the last 12 months, operating cash flow was 55.18 billion and capital expenditures -3.10 billion, giving a free cash flow of 52.08 billion.

Operating Cash Flow	55.18B
Capital Expenditures	-3.10B
Depreciation & Amortization	13.80B
Net Borrowing	-8.94B
Free Cash Flow	52.08B
FCF Per Share	n/a

Margins

Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.

Gross Margin	78.84%
Operating Margin	40.14%
Pretax Margin	33.27%
Profit Margin	28.90%
EBITDA Margin	49.51%
EBIT Margin	40.14%
FCF Margin	32.12%

Dividends & Yields

This stock pays an annual dividend of 5.78, which amounts to a dividend yield of 1.81%.

Dividend Per Share	5.78
Dividend Yield	1.81%
Dividend Growth (YoY)	-3.96%
Years of Dividend Growth	2
Payout Ratio	47.04%
Buyback Yield	0.24%
Shareholder Yield	2.05%
Earnings Yield	5.94%
FCF Yield	6.60%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.9 and a Piotroski F-Score of 7.

Altman Z-Score	3.9
Piotroski F-Score	7